Insiders · ATYR

ATYR insider transactions

aTyr Pharma Inc. (ATYR) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

ATYR insiders

Everyone who has filed a Form 3, 4, 5 or 144 at aTyr Pharma Inc., latest first. Follow anyone to get their next filing.

• Brandon YarasChief Financial Officer, since October 2026
• Paul SchimmelDirector+$3.8M
• Timothy CoughlinDirector+$87.5K
• Eric BenevichDirector, since December 2024
• Jane A GrossDirector+$15K
• Svetlana LucasDirector
• Sara ZaknoenDirector, since May 2021
• Sanjay ShuklaPresident and CEO, Director+$221K-$9,615
• Jill Marie BroadfootChief Financial Officer+$21.9K-$15.6K
• Nancy DenyesGeneral Counsel+$9,276-$4,490
• John K ClarkeDirector-$10.9K

Recent Form 3, 4, and 5 filings for ATYR

• 38d
  SEC Form 4 filed by Chief Financial Officer Yaras Brandon

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 38d
  SEC Form 3 filed by new insider Yaras Brandon

  3 - aTYR PHARMA INC (0001339970) (Issuer)
• 164d
  Director Schimmel Paul bought $49,630 worth of shares (100,000 units at $0.50) (SEC Form 4)

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 179d
  SEC Form 4 filed by Director Coughlin Timothy

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 179d
  SEC Form 4 filed by Director Benevich Eric

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 179d
  SEC Form 4 filed by Director Gross Jane A

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 179d
  SEC Form 4 filed by Director Lucas Svetlana

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 179d
  SEC Form 4 filed by Director Zaknoen Sara

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 179d
  SEC Form 4 filed by Director Schimmel Paul

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 276d
  President and CEO Shukla Sanjay converted options into 10,375 shares and sold $3,655 worth of shares (3,745 units at $0.98), increasing direct ownership by 5% to 153,553 units (SEC Form 4)

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 276d
  Chief Financial Officer Broadfoot Jill Marie converted options into 3,750 shares and sold $1,521 worth of shares (1,558 units at $0.98), increasing direct ownership by 6% to 37,296 units (SEC Form 4)

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 276d
  General Counsel Denyes Nancy converted options into 2,687 shares and sold $1,091 worth of shares (1,118 units at $0.98), increasing direct ownership by 5% to 33,124 units (SEC Form 4)

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 302d
  SEC Form 4 filed by President and CEO Shukla Sanjay

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 302d
  SEC Form 4 filed by Chief Financial Officer Broadfoot Jill Marie

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 302d
  SEC Form 4 filed by General Counsel Denyes Nancy

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 394d
  Director Schimmel Paul bought $911,801 worth of shares (1,000,000 units at $0.91) (SEC Form 4)

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 554d
  SEC Form 4 filed by Director Zaknoen Sara

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 554d
  SEC Form 4 filed by Director Schimmel Paul

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 554d
  SEC Form 4 filed by Director Lucas Svetlana

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 554d
  SEC Form 4 filed by Director Gross Jane A

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 554d
  SEC Form 4 filed by Director Benevich Eric

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 554d
  SEC Form 4 filed by Director Coughlin Timothy

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 600d
  Director Gross Jane A bought $15,000 worth of shares (3,750 units at $4.00), increasing direct ownership by 62% to 9,750 units (SEC Form 4)

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 641d
  President and CEO Shukla Sanjay converted options into 10,375 shares, increasing direct ownership by 8% to 146,923 units (SEC Form 4)

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 641d
  Chief Financial Officer Broadfoot Jill Marie converted options into 3,750 shares and sold $4,740 worth of shares (1,254 units at $3.78), increasing direct ownership by 9% to 31,763 units (SEC Form 4)

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 641d
  General Counsel Denyes Nancy sold $3,398 worth of shares (899 units at $3.78) and converted options into 2,687 shares, increasing direct ownership by 7% to 26,555 units (SEC Form 4)

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 666d
  SEC Form 4 filed by President and CEO Shukla Sanjay

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 666d
  SEC Form 4 filed by Chief Financial Officer Broadfoot Jill Marie

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 666d
  SEC Form 4 filed by General Counsel Denyes Nancy

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 695d
  SEC Form 4 filed by Director Benevich Eric

  4 - aTYR PHARMA INC (0001339970) (Issuer)
• 695d
  SEC Form 3 filed by new insider Benevich Eric

  3 - aTYR PHARMA INC (0001339970) (Issuer)
• 836d
  Director Schimmel Paul bought $184,613 worth of shares (100,000 units at $1.85) (SEC Form 4)

  4 - aTYR PHARMA INC (0001339970) (Issuer)